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 Abstract 
 Background : The Enhanced Liver Fibrosis (ELF) score 
combining serum hyaluronan, N-terminal peptide of type III 
procollagen and tissue inhibitor of metalloproteinase-1, was 
reported as relevant in predicting liver fi brosis in chronic liver 
disease and proposed as an alternative to liver biopsy. 
 Methods : We evaluated the ELF score in a cohort of chronic 
hepatitis C (CHC) patients included in a multicenter prospec-
tive study (ANRS HC EP 23 Fibrostar) using commercial 
reagents, different from those developed by the manufacturer 
of the Siemens ELF™ test. 
 Results : In 512 CHC, the ELF score, using ROC curves, 
showed good predictive performances for severe fi brosis 
[AUROC = 0.82; 95 % confi dence interval (CI) 0.78 – 0.86]
and for cirrhosis (AUROC = 0.85; 95 % CI 0.81 – 0.90), but 
slightly lower for signifi cant fi brosis (AUROC = 0.78; 95 % CI 
0.74 – 0.82). The Obuchowski measure (0.81) showed that the 
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ELF score globally performed as a marker of liver fi brosis. 
The ELF score predicted signifi cant fi brosis (cut-off = 9.0) 
with a sensitivity of 0.86, a specifi city of 0.62, a positive pre-
dictive value (PPV) of 0.80 and a negative predictive value 
(NPV) of 0.70. For extensive fi brosis (cut-off = 9.33), sensi-
tivity was 0.90, specifi city was 0.63, PPV was 0.73 and NPV 
was 0.85. For cirrhosis (cut-off = 9.35), sensitivity was 0.83, 
specifi city was 0.75, PPV was 0.44 and NPV was 0.95. 
 Conclusions : This study confi rms the ELF score performance 
as an index to predict liver fi brosis or cirrhosis in CHC. The 
ELF test, using validated reagents, could be added to the 
health authorities approved non-invasive tests in assessing 
fi brosis as surrogate to liver biopsy. 
 Keywords:  blood marker;  diagnostic accuracy;  ELF test; 
 hepatitis C;  liver fi brosis. 
 Introduction 
 Clinical management of chronic hepatitis C (CHC) is 
largely depending on the extent of liver fi brosis. Liver his-
tological examination of the liver biopsy, although having 
some estimated disadvantages, was considered as the refer-
ence method to assess the fi brosis stage and was until now 
recommended in the majority of patients  (1) . However, it is 
an invasive procedure responsible for severe complications 
in about 0.5 % of cases  (2) and its accuracy in scoring liver 
fi brosis is limited by sampling heterogeneity and inter- and 
intra-observer variations  (3, 4) . Various non-invasive mark-
ers of liver fi brosis have been recently developed and were 
shown as interesting alternative to liver biopsy in order 
to evaluate the severity of liver fi brosis in patients with 
chronic liver diseases  (5, 6) . Three indices resulting of the 
combination of blood markers of liver fi brosis, Fibrotest® 
 (7) , Fibrometer®  (8) , and Hepascore®  (9) , have a good diag-
nostic accuracy in patients with CHC for discriminating 
mild fi brosis to severe fi brosis and for assessing cirrhosis. 
Recently, the Haute Autorit é de Sant é (HAS, the French 
National Authority for Health) has evaluated the benefi t of 
the available methods and considered that in adult patients 
with untreated CHC without any comorbidity, these three 
validated biological diagnostic tests  (10) have shown suf-
fi cient interest to be approved by the health authorities 
for the inscription to reimbursement. The authority stated 
that another algorithm, the European Liver Fibrosis Group 
(ELFG) score  (11) , has shown a potential interest but has 
not been fully validated, particularly in the diagnosis of cir-
rhosis and that further independent studies are needed to 
validate this test  (12) . 
 A multicenter prospective and independent study, designed 
to evaluate and to compare the diagnosis performance of 
published tests, defi nitely confi rmed the importance of 
these non-invasive markers to assess liver fi brosis in CHC. 
Fibrometer®, Hepascore®, and Fibrotest® performed better 
than all other blood tests and the diagnostic performances 
of ELFG score were not far from the most performing tests 
 (13) . The original ELFG score combines a panel of three 
serum biomarkers involved in the synthesis and degrada-
tion of extracellular matrix, hyaluronic acid (HA), amino-
terminal peptide of type III procollagen (PIIINP) and tissue 
inhibitor of metalloproteinase-1 (TIMP-1), with age. The 
ELFG score was recently simplifi ed by removing age and 
a new algorithm, the Enhanced Liver Fibrosis (ELF) score, 
was developed  (14) using the proprietary assays developed 
for Siemens ELF™ test (Siemens Healthcare Diagnostics 
Inc., Tarrytown, NY, USA) introduced onto the market this 
year. 
 To confi rm the clinical interest of the simplifi ed ELF score, 
we evaluated its diagnostic accuracy for the prediction of 
signifi cant fi brosis, severe fi brosis and cirrhosis in the cohort 
of CHC patients included in the ANRS HC EP 23 Fibrostar 
multicenter prospective study using METAVIR histological 
fi brosis stage as reference  (15) . The diagnostic performance 
of the simplifi ed ELF score was compared to the original 
ELFG score and to other serum tests validated as marker of 
liver fi brosis. Furthermore ELF score was assessed indepen-
dently both of the authors and of the manufacturer using other 
commercial assay kits than its own. 
 Materials and methods 
 The study was approved by the Committee for protection of persons 
of Grenoble (France). Informed consent was obtained from each 
patient. 
 Patients 
 Between November 2007 and July 2008, 19 academic centers pro-
spectively enrolled in a cohort study designed to compare different 
biological blood markers of liver fi brosis and transient elastography 
(Fibroscan™) 590 untreated patients with CHC (anti-HCV antibod-
ies positive and RNA-HCV positive) referred for evaluation, includ-
ing liver biopsy. 
 Patients with associated coinfection, chronic viral hepatitis B 
(HBsAg positive) or HIV, with other liver disease (drug hepatitis, 
Wilson disease, hemochromatosis, autoimmune hepatitis, alcohol 
consumption  > 30 g/day for men and  > 20 g/day for women, primary 
biliary cirrhosis,  α -1 antitrypsine defi ciency), or with severe systemic 
diseases were excluded. Patients with antiviral therapy during the 6 
months preceding the inclusion or with immunosuppressive therapy 
were also excluded. 
 Liver pathological examination 
 Histological analysis was independently performed by two senior 
pathologists, academic experts in liver pathology, without knowl-
edge of any clinical and biological data except that patients had 
chronic hepatitis C. To be considered as adequate for scoring, the 
liver biopsies had to measure at least 15 mm and/or contain at least 
11 portal tracts except for cirrhosis for which no limitation was 
required. Fibrosis was assessed on red Sirius stained sections 
according to the semi quantitative Metavir scoring system, on a 
fi ve-point scale (F0 = no fi brosis, F1 = portal fi brosis without septa, 
F2 = few septa, F3 = numerous septa without cirrhosis, F4 = cirrhosis) 
 (15) . In case of discrepancies, slides were simultaneously reviewed 
by the two pathologists using a multi-pipe microscope in order to 
reach a consensus. 
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 Blood samples 
 Fasting blood samples were collected by veinipuncture at  < 2 months 
away from the liver biopsies. The same kinds of tubes from the same 
lots were used for all the patients (BD Vacutainer, type Z, Becton-
Dickinson, Plymouth, UK). 
 Each of the biological parameters included in the ELF score were 
measured in a single laboratory using serum samples immediately 
separated and fractioned in fractions of 0.5 mL in 1.5 mL screw cap 
micro tubes (Sarstedt, N ü mbrecht, Germany). All the fractions were 
immediately frozen and stored at  – 80 ° C until the assays were under-
taken. The transport of samples from the hepatology centers to the 
laboratory were achieved in carbonic ice by a specialized transporter 
(AreaTime Logistics, Cergy Pontoise, France). 
 All the biological tests were processed blindly without knowledge 
of the clinical and histological data. 
 ELF score 
 ELF score biochemical assays  The serum HA was assayed using 
a latex agglutination method that can be applied to general clinical 
chemistry analyzers (HA detection reagent, Latex method, Wako, 
Osaka, Japan) using an AU640 analyzer (Beckman Coulter, Brea, 
CA, USA) as previously described  (16) . The serum PIIINP was 
assayed using a radio immunoassay (P3NP RIA kit, Orion Diagnostica, 
Espoo, Finland), and the serum TIMP-1 was assayed using an Elisa 
kit (TIMP-1 Biotrak ELISA, GE Healthcare Lifesciences, Chalfont 
St. Giles, UK) as previously described  (17) . 
 ELF score calculation  The ELF score was computed from 
the results by using the simplifi ed algorithm with reference to 
Metavir classifi cation of liver biopsy, published by Parkes et al. 
 (14) : ELF score = – 7.412 + [ln HA (ng/mL) × 0.681] + [ln PIIINP 
(ng/mL) × 0.775] + [ln TIMP1 (ng/mL) × 0.494] + 10. 
 ELFG score calculation  The ELFG score was computed from 
the results by using the simplifi ed algorithm with reference to 
Metavir classifi cation of liver biopsy, published by Rosenberg et al. 
 (11) : ELFG score = – {0.014 ln [age (years)]} +{ 0.616 ln [hyaluronic 
acid (ng/mL)]} + {0.586 ln [PIIINP (ng/mL)]} + {0.472 ln [TIMP1 
(ng/mL)]} – 6.38. 
 Fibrotest 
 The serum parameters of Fibrotest® were strictly measured according 
to the technical recommendations of the authors, using the methods 
used to develop the test as described in the original publication  (7) . 
Specifi c protein assays [ α 2 -macroglobulin (A2M), haptoglobin, apo-
lipoprotein A1] were measured by immunonephelemetric methods 
using a BN2 analyzer (Siemens Healthcare Diagnostics, Deerfi eld, 
USA).  γ -Glutamyltransferase (GGT), alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) activities (IFCC meth-
ods at 37 ° C with pyridoxal phosphate for ALT and AST) and total 
bilirubin were measured using an Hitachi 917 analyzer (Roche 
Diagnostics, Mannheim, Germany) with reagents from the manu-
facturer and a CFAS (Calibrator for Automated Systems, Roche 
Diagnostics) calibration. Calculations of the scores were purchased 
from Biopredictive (Paris, France). 
 Hepascore 
 An OLYMPUS AU640 (Olympus Diagnostic Systems, Tokyo, 
Japan) analyzer was used for simultaneous assays of the parameters 
included in the Hepascore®. Serum HA levels were assayed using 
a latex agglutination method (HA detection reagent, Latex method, 
Wako, Osaka, Japan). A2M levels were measured using an immu-
noturbidimetric assay (α-2-Macroglobulin kit, DakoCytomation, 
Glostrup, Denmark). GGT activities (IFCC method at 37 ° C) and total 
bilirubin concentrations were assayed using Olympus reagents with 
CFAS calibration (Roche Diagnostic). The Hepascore was computed 
from the results by using the model previously published by Adams 
et al.  (9) : Hepascore = y/(1 + y) with y = exp { – 4.185818 – [0.0249 age 
(years)] + [0.7464 sex (M = 1 , F = 0)] + [1.0039 A2M (g / L)] + [0.0302 
HA ( μ g / L)] + [0.0691 bilirubin ( μ mol / L)] – [0.0012 GGT (IU / L)]}. 
 Statistical analysis 
 GraphPad Prism computer software was used for statistical analy-
sis (GraphPad Software, La Jolla, CA USA). Quantitative variables 
are expressed as mean (SD) or median (range) as specifi ed. The 
Kruskal-Wallis analysis of variance was used to compare the ELF 
score results according to the histological scores of fi brosis and the 
Spearman rank correlation to assess the relationship between ELF 
score and histological degree of fi brosis. A p-value of  < 0.05 was 
considered statistically signifi cant. 
 Receiver-operator characteristic (ROC) curves were built to visu-
alize the discriminating performance of the ELF score considering 
liver biopsy as the reference. Areas under the ROC curves (AUROC) 
were calculated to quantify the ability of the test to discriminate 
between fi brosis grades. The optimal cut-offs were calculated by 
maximizing the sum of sensitivity plus specifi city. 
 Given the ordinal scaling of histological fi brosis, the Obuchowski 
measure was used to estimate the overall diagnostic performance of 
the ELF test and to compare it with the diagnostic performances of 
other tests. This measure can be used as an estimator for test accu-
racy when the gold standard is not binary but graded on an ordinal 
scale  (18) . Since no assumptions on the distribution of the gold stan-
dard are needed, it is insensitive to the distribution of fi brosis stages 
in the study sample and was recently recommended as a multino-
mial version of the AUROC to assess diagnostic accuracy of liver 
fi brosis tests without the spectrum bias due to the prevalence of the 
different stages of liver fi brosis in the studied cohort of patients  (19) . 
The Obuchowski measures were calculated online ( http://www.info.
univ-angers.fr/~gh/wstat/obu_f.php, by courtesy of Dr. G. Hunault, 
Angers University, Angers, France ) using the observed prevalence 
for each group of patients and a penalty function that was propor-
tional to the difference in METAVIR units as recommended  (19) . 
 Results 
 Patient characteristics 
 Because of insuffi cient liver tissue (n = 42), previous inter-
feron therapy (n = 5), coexisting liver disease due to chronic 
HBV infection (n = 9), excessive alcohol consumption (n = 5), 
immunosuppressive treatment (n = 1), non-confi rmed HCV 
positive status (n = 3), or incomplete data (n = 13), the fi nal 
study cohort included 512 patients, 306 male (59.8 % ) and 
206 female (40.2 % ). The characteristics of the patients were 
summarized in Table  1 . 
 Liver histology 
 The length of liver biopsies was 25.1 ± 8.8 mm (mean ± SD) 
and longer than 25 mm in 49.8 % . Metavir stages distribution 
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 Table 1  Characteristics of the 512 studied patients. 
Median Range
Age, years  50 18 – 79
Weight, kg  70 39 – 135
Height, m 1.70  1.48 – 1.97
BMI, kg/m 2  24.3 15.4 – 49.2
Bilirubin,  μ mol/L  10.5  2.4 – 54.8
ALT, IU/L  69 12 – 594
AST, IU/L  49 11 – 280
GGT, IU/L  61  9 – 858
Platelet count, g/L 213 52 – 474
Prothrombin time,  %  99 61 – 100
Hyaluronic acid, ng/mL  34  5 – 920
PIIINP, ng/mL  4.5  1.4 – 69.7
TIMP-1, ng/mL 160  4.9 – 653
was F0 in 34 (6.6 % ), F1 in 231 (45.1 % ), F2 in 92 (18.0 % ), F3 
in 79 (15.4 % ) and F4 in 76 (14.8 % ) patients. 
 Assessment of liver fi brosis using the ELF score 
 Figure  1 shows box plot for ELF scores according to the 
Metavir stages of liver fi brosis. ELF score increased with 
histological stage of liver fi brosis with signifi cant differ-
ences between groups (p < 0.0001, Kruskall-Wallis test). 
There was a signifi cant correlation between Metavir fi brosis 
stage and ELF score [r = 0.554 (95 % confi dence interval CI 
0.489 – 0.613), p < 0.0001, Spearman’s rank correlation]. 
 The ROC curve analyses showed the diagnostic perfor-
mances of the automated ELF score to discriminate signifi -
cant fi brosis (F ≥ 2), severe fi brosis (F ≥ 3) and cirrhosis (F4) in 
patients with CHC (Figure  2 ). The areas under the ROC curves 
(Table  2 ) showed good performances (AUROC higher than 
0.80) for severe fi brosis (AUROC = 0.82; 95 % CI 0.74 – 0.82) 
and for cirrhosis (AUROC = 0.85; 95 % CI 0.81 – 0.90), but 
slightly lower diagnostic performances for signifi cant fi bro-
sis (AUROC = 0.78; 95 % CI 0.74 – 0.82). AUROC were not 
signifi cantly different when using the original ELFG score, 
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 Figure 2  ROC curves for ELF score predictive value of signifi cant 
fi brosis ( ≥ F2), severe fi brosis ( ≥ F3) and cirrhosis (F4) in patients 
with chronic hepatitis C. 
respectively: 0.780 (CI 0.74 – 0.82) for diagnostic of signifi -
cant fi brosis; 0.82 (CI 0.78 – 0.86) for diagnostic of extensive 
fi brosis and 0.85 (CI 0.81 – 0.90) for diagnostic of cirrhosis. 
 The performances of the ELF score for identifi cation of 
signifi cant fi brosis, severe fi brosis or cirrhosis are shown in 
Table  3 . 
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 Table 2  Area under ROC curves (95 % CI) for ELF score according to fi brosis stage. Comparison with previous studies. 
Parkes et al.  (14) This study
Original cohort Cohort 1 Cohort 2 Cohort 3
Patients number 921 87 173 87 512
Fibrosis stage
  Scheuer F0/F1/F2/F3/F4,  %  24/36/13/15/12
METAVIR F0/F1/F2/F3/F4,  % 10/33/32/10/14  7/45/18/15/15
  Ishak 0/1/2/3/4/5/6,  %  20/15/117/12/7/11/17  1/16/27/21/8/16/10
For signifi cant fi brosis diagnosis
  AUROC  0.79  0.74  0.83  0.87  0.78
  (95 % CI)  (0.76 – 0.82) (0.63 – 0.84)  (0.76 – 0.89) (0.80 – 0.95)  (0.74 – 0.82)
For severe fi brosis diagnosis
  AUROC  0.83  0.84  0.86  0.89  0.82
  (95 % CI)  (0.80 – 0.86) (0.74 – 0.94)  (0.80 – 0.92) (0.83 – 0.96)  (0.78 – 0.86)
For cirrhosis diagnosis
  AUROC  0.86  0.90  0.8  0.89  0.85
  (95 % CI)  (0.83 – 0.89) (0.81 – 0.98)  (0.81 – 0.93) (0.82 – 0.96)  (0.81 – 0.90)
 Comparison of the ELF score with other serum 
markers of liver fi brosis 
 The Obuchowski measure was 0.81 (95 % CI 0.78 – 0.84) show-
ing that ELF score globally performed as a biochemical marker 
of liver fi brosis. In the same 512 patients, the diagnostic accuracy 
of the simplifi ed ELF score was equivalent to the original ELFG 
score (Obuchowski measure: 0.81; p = 0.292). The comparisons 
with other serum marker of liver fi brosis showed that ELF score 
had better diagnostic accuracy than hyaluronic acid serum level 
(Obuchowski measure: 0.78; p = 0.006) but slightly less per-
formed than Fibrotest® (Obuchowski measure: 0.82; p = 0.292) 
or Hepascore® (Obuchowski measure: 0.83; p = 0.053). 
 Discussion 
 The prognosis of chronic liver diseases is closely related to 
the development of liver fi brosis which commonly occurs 
as the disease progresses. In chronic hepatitis C, liver fi bro-
sis has to be evaluated both as a prognostic index and as a 
criterion in the treatment decision. Furthermore, when cir-
rhosis, the end-stage consequence of progressive fi brosis, is 
evidenced, the assessment of the risk of severe complications 
occurrence, including ascites, variceal bleeding, encephalo-
pathy, and hepatocellular carcinoma, has important clinical 
and therapeutical implications. 
 With the specifi c aim of replacing pathological examina-
tion of liver biopsy, various non-invasive tests of liver fi bro-
sis have been developed for monitoring patients with CHC 
infection  (5 – 14) . These include routinely available labora-
tory tests, such as liver-associated chemistries, A2M, platelet 
count, and prothrombin time, as well as specifi c serum mark-
ers of fi brosis, such as serum hyaluronic acid, PIIINP, matrix 
metalloproteinases and their inhibitors. 
 Until now, there are no FDA approved tests and the 
American recommendations  (20, 21) have considered that 
currently available non-invasive tests may be useful in defi n-
ing the presence or absence of advanced fi brosis in persons 
with chronic hepatitis C infection, but should not yet replace 
the liver biopsy in routine clinical practice. The French 
National Authority for Health has considered that in chronic 
untreated hepatitis C adult patients with no co-morbidities 
three biological tests have been validated as non-invasive 
procedures for liver fi brosis evaluation and/or cirrhosis diag-
nostic [Fibrotest®  (7) , FibroMeter®  (8) and Hepascore®  (9) ] 
and recommended  (10) to use one of them or liver biopsy 
or transient elastography [FibroScan™  (22) ] as fi rst-line 
test. In France, these four tests have recently received this 
year the agreement for reimbursement by the mandatory 
health insurance in this indication. About the ELFG score, 
the health authority and the recommendations have speci-
fi ed that this non-invasive test has shown a potential clinical 
benefi t in the same indication but with insuffi cient scientifi c 
 Table 3  ELF score performance for identifi cation of signifi cant fi brosis, severe fi brosis or cirrhosis in patients with chronic hepatitis C. 
For signifi cant fi brosis For severe fi brosis For cirrhosis
Cut-off 9.0 9.33 9.35
Sensitivity (95 % CI) 0.86 (0.81 – 0.90) 0.90 (0.87 – 0.93) 0.83 (0.79 – 0.66)
Specifi city (95 % CI) 0.62 (0.55 – 0.68) 0.63 (0.55 – 0.71) 0.75 (0.64 – 0.84)
Positive predictive value 0.80 0.73 0.44
Negative predictive value 0.70 0.85 0.95
Youden index 0.47 0.53 0.59
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data to consider it as totally validated, requiring complemen-
tary and independent confi rmation studies  (12, 23) . Since 
complementary and independent confi rmation studies were 
required, we have chosen to evaluate the ELF score in a large 
cohort (n = 512) of patients with CHC included in a prospec-
tive controlled study. Using the simplifi ed ELF score did 
not alter the diagnostic performance of the test since it was 
equivalent using the original ELFG score. However, the ELF 
score performs slightly less than Fibrotest® or Hepascore® 
as previously shown for the ELFG score  (13) . Since it is 
well documented that the variability of liver biopsy is not 
negligible, and it was shown that the histological staging of 
needle biopsy specimens is impaired both by variation in the 
severity of the diseases in different parts of the liver and by 
observer variability  (3, 4) the rigorous pathological examina-
tion of liver biopsies was a criterion of this study. All patients 
had liver biopsies of good sizes ( > 15 mm and/or  > 10 portal 
tracts with a mean length of 25 mm) reviewed by two inde-
pendent senior hepato-pathologists, enough for optimizing 
the histopathological analysis as previously shown  (24) . In 
comparison, other cohorts for simplifi ed ELF score valida-
tion  (14) included less patients (n = 87, 173, 87) without crite-
rion of liver biopsies size (Table  2 ). 
 Our results confi rm previous data shown with the original 
ELFG score  (11) and with the simplifi ed ELF score in chronic 
hepatitis C  (14) , or in chronic liver diseases of various etiolo-
gies  (24) . The Obuchowski measure, an adjusted-on-fi brosis-
stages distribution AUC, shows that the ELF score globally 
performs as a biochemical marker of liver fi brosis. It can be 
interpreted as the probability that the ELF score will correctly 
rank two randomly chosen patient samples from different 
fi brosis grades. The areas under the ROC curves showed good 
performances (AUROC higher than 0.80) for severe fi brosis 
and for cirrhosis diagnostics. Slightly lower diagnostic per-
formances were shown for signifi cant fi brosis diagnostic 
(AUROC = 0.78) as in the original cohort (AUROC = 0.79) and 
another study (AUROC = 0.78)  (14, 25) . Globally, the diag-
nostic performances of the simplifi ed ELF score, as those of 
the original ELFG score, are only slightly lower the diagnos-
tic performances of Fibrometer®, Hepascore®, and Fibrotest®, 
the most performing tests and noticeably better than HA, 
APRI, Forns ’ or FIB-4  (13) . 
 Since the diagnosis of cirrhosis is important the high NPV 
for excluding cirrhosis (95 % ) could be useful in clinical prac-
tice to avoid a number of liver biopsies. 
 We used commercial assays for serum measurements of the 
ELF score components (HA, PIIINP, TIMP-1) independently 
of the proprietary assays developed by Siemens Healthcare 
Diagnostics Inc., which were not yet marketed at the time of 
the study. Our results show the robustness of the ELF score 
since it confi rms its diagnostic value with other assay meth-
ods. While the methods we used for TIMP 1 and PIIINP are 
sophisticated, time consuming and onerous, only HA assay 
can be automatized using general clinical chemistry analyz-
ers, an advantage of the ELF score is that it can be totally 
automated using the captive reagents for the Siemens ELF™ 
test that necessitate a single analyzer and only one serum 
sample, like it is possible for the Hepascore®  (26) or for the 
Fibrotest® (27) but not for the scores including platelets count 
or prothrombin time like the Fibrometer®, APRI, FIB-4 or 
Forns ’ score. However, since ELF score components are not 
specifi c of liver fi brosis, more studies are needed to determine 
the best use of the test. 
 In conclusion, our results show that ELF score parameters 
can be assayed with other validated reagents than those origi-
nally used and confi rm the diagnostic value of the simplifi ed 
ELF score in evaluating the liver fi brosis in patients with 
chronic hepatitis C. This test might be added to the non-in-
vasive biological tests approved by the health authorities in 
this indication. 
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